A Study Of Atezolizumab Compared With Chemotherapy ... - Cli…
Atezolizumab with or without chemotherapy in metastatic
Atezolizumab With Or Without Chemotherapy In Metastatic …
Atezolizumab and bladder cancer: facing a complex disease - The Lancet
A Study Of Atezolizumab Versus Placebo As Adjuvant ... - …
Atezolizumab with or without chemotherapy in metastatic
A Study Of Atezolizumab Compared With Chemotherapy …
Atezolizumab with or without chemotherapy in metastatic
Atezolizumab FDA Indication For Pretreated Bladder …
Methods: In this multicentre, phase 3, randomised trial, untreated patients aged 18 years or older with locally advanced or metastatic urothelial carcinoma, from 221 sites in 35 countries, were randomly assigned to receive atezolizumab plus platinum-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based chemotherapy (group C).
Phase 3 Trial Of Atezolizumab For Urothelial Cancer Misses Primary …
09/12/2020 · This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy. Study Design Go to
Images Of Atezolizumab Bladder Cancer Phase 3
27/11/2014 · This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen.
Atezolizumab Falls Short In Phase III Bladder Cancer Trial
08/03/2021 · March 8, 2021. Jason M. Broderick. The withdrawal comes after the confirmatory phase 3 IMvigor211 study missed its primary end point. Roche (Genentech) has voluntarily withdrawn the FDA indication for the PD-L1 inhibitor atezolizumab (Tecentriq) for use in patients with locally advanced or metastatic urothelial carcinoma (mUC) previously treated ...
Atezolizumab Misses Primary Endpoint In Phase III Bladder Cancer …
27/01/2020 · Adjuvant atezolizumab failed to extend DFS compared with observation among patients with muscle-invasive urothelial cancer, according to topline results of a randomized phase 3 trial released by...
Atezolizumab With Or Without Chemotherapy In Metastatic …
10/05/2017 · Atezolizumab Falls Short in Phase III Bladder Cancer Trial May 10, 2017 Jason M. Broderick Atezolizumab missed the phase III IMvigor211 trial’s primary endpoint of improving overall survival in the...